Literature DB >> 19949764

[Advanced malignant soft tissue tumors: plastic reconstructive options for palliative treatment].

P M Vogt1, A Jokuszies.   

Abstract

Plastic and reconstructive procedures for the oncological treatment of malignant tumors in the head and neck region, trunk and extremities are primarily curative. Less is known about the treatment options of plastic surgery in patients with locally advanced or incurable tumors. Therefore superficial, mostly exulcerated and superinfected tumors are treated with a palliative approach. A plethora of symptoms drastically restricts the quality of life in patients with advanced cancer. Pain, oozing of blood and bacterial superinfection with fetidness compromise the patient's general condition, self-esteem and activity. Many patients suffer from increasing isolation. A stage-adapted and plastic-reconstructive approach aiming at reducing the tumor mass and closing ulcerating wounds provides a considerable benefit especially in these patients. In this article a variety of treatment options regarding palliative resections and plastic reconstructive procedures and the disease alleviating benefits for patients with incurable tumors are presented.

Entities:  

Mesh:

Year:  2010        PMID: 19949764     DOI: 10.1007/s00104-009-1841-6

Source DB:  PubMed          Journal:  Chirurg        ISSN: 0009-4722            Impact factor:   0.955


  13 in total

1.  [Plastic reconstruction of postoncologic defects in the pelvic area].

Authors:  P M Vogt; A Jokuszies; S Kall; A Steiert; K Busch
Journal:  Zentralbl Chir       Date:  2006-12       Impact factor: 0.942

2.  Evidence-based interventions to improve the palliative care of pain, dyspnea, and depression at the end of life: a clinical practice guideline from the American College of Physicians.

Authors:  Amir Qaseem; Vincenza Snow; Paul Shekelle; Donald E Casey; J Thomas Cross; Douglas K Owens; Paul Dallas; Nancy C Dolan; Mary Ann Forciea; Lakshmi Halasyamani; Robert H Hopkins; Paul Shekelle
Journal:  Ann Intern Med       Date:  2008-01-15       Impact factor: 25.391

3.  [Greater omentumplasty for covering the chest wall following removal of ulcerating breast cancer].

Authors:  J Durst; J Hoch
Journal:  Langenbecks Arch Chir       Date:  1986

4.  The ASA Physical Status Classification: inter-observer consistency. American Society of Anesthesiologists.

Authors:  P H K Mak; R C H Campbell; M G Irwin
Journal:  Anaesth Intensive Care       Date:  2002-10       Impact factor: 1.669

5.  When radiotherapy offers no more: the surgical management of advanced breast malignancy.

Authors:  R Sanders; T E Goodacre
Journal:  Ann R Coll Surg Engl       Date:  1989-11       Impact factor: 1.891

Review 6.  [Somatic sequelae of radiotherapy: the possibility of surgery].

Authors:  S Basso Ricci
Journal:  Minerva Chir       Date:  1989-10-15       Impact factor: 1.000

7.  [Surgical treatment of metastases of the acetabulum].

Authors:  J Duparc; D Huten; E Benfrech
Journal:  Rev Chir Orthop Reparatrice Appar Mot       Date:  1989

Review 8.  [Palliative surgery for primary and secondary thoracic malignancies].

Authors:  R Inderbitzi; A Rolle
Journal:  Ther Umsch       Date:  2001-07

9.  Extensive and complex defects of the scalp, middle third of the face, and palate: the role of microsurgical reconstruction.

Authors:  N F Jones; R A Hardesty; W M Swartz; S S Ramasastry; F R Heckler; E D Newton
Journal:  Plast Reconstr Surg       Date:  1988-12       Impact factor: 4.730

10.  Brachytherapy tubes and free tissue transfer after soft tissue sarcoma resection.

Authors:  Kamran Aflatoon; Mark W Manoso; E Gene Deune; Deborah A Frassica; Frank J Frassica
Journal:  Clin Orthop Relat Res       Date:  2003-10       Impact factor: 4.176

View more
  1 in total

1.  [Microsurgical reconstruction of the pelvic floor after pelvic exenteration. Reduced morbidity and improved quality of life by an interdisciplinary concept].

Authors:  N M Stechl; S Baumeister; K Grimm; T W Kraus; H Bockhorn; K E Exner
Journal:  Chirurg       Date:  2011-07       Impact factor: 0.955

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.